Acquisition Expands 10x Genomics' Capabilities in Proteomics

此次收购拓展了10x Genomics在蛋白质组学领域的能力

PLEASANTON, Calif.

加利福尼亚州普莱森顿

,

，

June 9, 2026

2026年6月9日

/PRNewswire/ --

/美通社/ --

10x Genomics, Inc

10x Genomics 公司

. (Nasdaq:

.（纳斯达克：

TXG

TXG

), the life science technology leader focused on accelerating science and advancing human health, today announced the acquisition of Proteintech Genomics, a division within Proteintech Group, a company specializing in developing high-plex proteomic solutions for single cell and spatial applications on 10x platforms..

），这家专注于加速科学发展和促进人类健康的生命科学技术领导者，今天宣布收购Proteintech Genomics，这是Proteintech集团旗下的一个部门，该公司专门致力于为10x平台开发用于单细胞和空间应用的高通量蛋白质组学解决方案。

The acquisition marks a strategic expansion of 10x's proteomics capabilities. Proteintech Genomics brings differentiated technologies, including its Human Discovery Panel, the largest antibody-based single cell protein panel, designed to support integrated analysis of intracellular proteins, cell surface proteins and transcriptomic profiles within sequencing-compatible workflows.

此次收购标志着10x公司在蛋白质组学能力方面的战略扩张。Proteintech Genomics带来了差异化技术，包括其“人类发现面板”（Human Discovery Panel），这是最大的基于抗体的单细胞蛋白面板，旨在支持在兼容测序的工作流程中对细胞内蛋白、细胞表面蛋白和转录组谱进行整合分析。

The Human Discovery Panel is compatible with Flex chemistry, including the Flex Apex assay..

人类发现面板与Flex化学兼容，包括Flex Apex检测。

'We believe the future of biological analysis will increasingly integrate transcriptomic and proteomic information at the single cell and spatial levels,' said Michael Schnall-Levin, Chief Technology Officer, Chief Strategy Officer and Founding Scientist of 10x Genomics. 'The acquisition of Proteintech Genomics expands our capabilities in proteomics and supports our broader vision for richer multiomic approaches to understanding biology.'.

10x Genomics 首席技术官、首席战略官兼创始科学家 Michael Schnall-Levin 表示：“我们相信，生物分析的未来将日益在单细胞和空间层面上整合转录组学和蛋白质组学信息。收购 Proteintech Genomics 将增强我们在蛋白质组学方面的能力，并支持我们更广泛的愿景，即通过更丰富的多组学方法来深入理解生物学。”

The acquisition builds on 10x's broader vision to enable multimodal biological analysis across the company's single cell and spatial platforms, including protein capabilities planned for the recently launched Atera platform.

此次收购进一步巩固了10x Genomics的更广泛愿景，即在其单细胞和空间平台上实现多模态生物分析，包括为最近推出的Atera平台规划中的蛋白质分析能力。

Researchers increasingly combine transcriptomic and proteomic-based measurements to gain complementary insights into cellular identity, state and function. These approaches have helped advance discovery across immunology, oncology, neuroscience and broader cell biology research. Today, researchers often rely on multiple vendors and workflows to harmonize RNA and protein analysis in single cell experiments..

研究人员越来越多地结合基于转录组学和蛋白质组学的测量方法，以获得对细胞身份、状态和功能的互补性见解。这些方法有助于推动免疫学、肿瘤学、神经科学以及更广泛的细胞生物学研究领域的发现。如今，在单细胞实验中，研究人员通常依赖多家供应商和工作流程来协调RNA和蛋白质分析。

'From day one, Proteintech Genomics was built around the belief that RNA and protein measurements are most powerful when used together. Because our technologies were designed to integrate with 10x workflows, joining the 10x team feels like a natural next chapter. We are excited about the opportunity to accelerate innovation together and expand access to integrated multiomic approaches for researchers around the world,' said Dr.

“从成立之初，Proteintech Genomics 就秉持一个信念：RNA 和蛋白质测量在联合使用时最具威力。由于我们的技术旨在与 10x 工作流程整合，加入 10x 团队仿佛是顺理成章的下一步。我们对于能够携手加速创新、并让全球研究人员更广泛地获得整合多组学方法的机会感到兴奋。”博士表示。

Kristopher Nazor, CEO of Proteintech Genomics. 'Single cell and spatial biology has always promised a more complete picture of cellular state - protein and RNA together, at scale, across tissues. We're finally in a position to deliver on that promise.'.

Proteintech Genomics 首席执行官 Kristopher Nazor 表示：“单细胞和空间生物学一直承诺提供更完整的细胞状态图景——在大规模下，跨组织同时分析蛋白质和 RNA。我们终于有能力兑现这一承诺。”

Proteintech Genomics' protein panels were purpose-built for 10x single cell workflows and are already used by many researchers to simultaneously analyze RNA and protein. The acquisition brings together 10x's expertise in scalable single cell and spatial biology platforms with Proteintech Genomics' advanced capabilities in protein detection..

Proteintech Genomics 的蛋白面板专为 10x 单细胞工作流程量身打造，已被众多研究人员用于同时分析 RNA 和蛋白质。此次收购将 10x 在可扩展单细胞和空间生物学平台方面的专业知识与 Proteintech Genomics 在蛋白质检测方面的先进能力相结合。

'Biology is bigger than transcriptomics alone. Bringing scalable protein measurements into single cell and spatial biology is an important step toward richer, more predictive views of cellular state — and ultimately, virtual cell models that better reflect the complexity of living systems,' said Ci Chu, Senior Vice President, AI-Enabled Discovery, Xaira Therapeutics..

“生物学的范畴远不止转录组学。将可扩展的蛋白质测量技术引入单细胞和空间生物学，是迈向更丰富、更具预测性的细胞状态视图的重要一步，并最终促成能够更好反映生命系统复杂性的虚拟细胞模型，”Xaira Therapeutics公司人工智能赋能发现高级副总裁Ci Chu表示。

For more than a decade, 10x has pioneered technologies that have transformed how scientists measure and understand biology. The acquisition of Proteintech Genomics continues that legacy, expanding the company's multiomic capabilities and reinforcing its commitment to developing breakthrough technologies that accelerate the mastery of biology and advance human health..

十多年来，10x Genomics 开创了多项技术，彻底改变了科学家测量和理解生物学的方式。对 Proteintech Genomics 的收购延续了这一传统，不仅扩展了公司的多组学能力，还进一步强化了其致力于开发突破性技术的承诺，以加速人类对生物学的掌握并推动人类健康的发展。

The terms of the transaction were not disclosed. 10x Genomics believes the transaction will not meaningfully impact its near-term financial outlook.

交易条款未予披露。10x Genomics 认为，该交易不会对其近期财务前景产生重大影响。

About 10x Genomics

关于 10x Genomics

10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology.

10x Genomics 是一家生命科学科技公司，致力于开发加速掌握生物学规律并推动人类健康进步的产品。我们的集成化研究解决方案包括用于单细胞和空间生物学的仪器、耗材及软件，帮助学术研究人员、转化医学研究者以及生物制药公司以与生物学复杂性相匹配的分辨率和规模来理解生物系统。

Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit .

我们的产品助力肿瘤学、免疫学、神经科学等领域取得突破性进展，推动强有力的发现，改变全球对健康与疾病的认知。欲了解更多信息，请访问。

10xgenomics.com

10xgenomics.com

or connect with us on

或通过以下方式联系我们

LinkedIn

领英

,

，

X

X

,

，

Facebook

脸书

,

，

Bluesky

蓝天

or

或

YouTube

YouTube

.

。

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections.

本新闻稿包含1933年《证券法》（经修订）第27A条和1934年《证券交易法》（经修订）第21E条所指的“前瞻性陈述”，这些陈述受上述条款所设立的“安全港”规则的保护。

All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as 'may,' 'might,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'see,' 'estimate,' 'predict,' 'potential,' 'would,' 'likely,' 'seek' or 'continue' or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking.

本新闻稿中包含的所有陈述，除历史事实陈述外，均可能构成前瞻性陈述。前瞻性陈述通常可通过使用前瞻性术语来识别，例如“可能”、“也许”、“将”、“应当”、“预期”、“计划”、“预计”、“能够”、“打算”、“目标”、“规划”、“考虑”、“相信”、“认为”、“估计”、“预测”、“潜在”、“会”、“很可能”、“寻求”或“继续”，或这些术语的否定形式、变体或类似术语，但未出现这些词语并不意味着某项陈述不属于前瞻性陈述。

These forward-looking statements include statements regarding 10x Genomics, Inc.'s acquisition of Proteintech Genomics, Inc., integration activities, potential commercial reach, potential impacts of its products and services and potential products, applications and capabilities and financial outlook.

这些前瞻性陈述包括关于10x Genomics, Inc.收购Proteintech Genomics, Inc.、整合活动、潜在商业覆盖范围、其产品和服务以及潜在产品、应用和能力的潜在影响，以及财务前景的陈述。

These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release.

这些陈述基于管理层当前的预期、预测、信念、假设以及目前可获得的信息。由于多种因素，实际结果可能与这些陈述存在重大差异，因此不应将这些陈述视为代表10x Genomics, Inc.在本新闻稿发布日期之后任何日期的观点。

10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any ch.

10x Genomics, Inc. 不承担任何义务，以更新任何前瞻性陈述来反映 10x Genomics 预期的任何变化或任何 ch。

Disclosure Information

披露信息

10x Genomics uses filings with the Securities and Exchange Commission, its website (

10x Genomics 使用向美国证券交易委员会提交的文件及其网站（

https://www.10xgenomics.com/

https://www.10xgenomics.com/

), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

）、新闻稿、公开电话会议、公开网络直播及其社交媒体账户，作为披露重大非公开信息以及履行其在《公平披露条例》（Regulation FD）下的披露义务的手段。

Contacts

联系人

Investors:

投资者：

[email protected]

[email protected]

Media:

媒体：

[email protected]

[email protected]

SOURCE 10x Genomics, Inc.

来源：10x Genomics, Inc.

21

二十一

%

%

more press release views with

更多新闻稿浏览量

Request a Demo

申请演示